Medigard Of Australia Cleared For Blood-Collection Device In U.S.
This article was originally published in PharmAsia News
Executive Summary
Australia's Medigard received U.S. FDA approval to sell its blood-collection medical device, marking the firm's entry into the major market. The company now plans to find a manufacturing partner to help it compete in the U.S.$300 million market for such devices. Medigard hopes to use its new U.S. presence to expand into the global market for syringes and needle-free injection tools, which it estimates to be worth U.S.$2.5 billion. (Click here for more